Clinical trial • Phase I • Oncology
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 antibody drug conjugate for Advanced solid tumors
Phase I trial of Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 antibody drug conjugate for Advanced solid tumors. 240 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors
- Trial Stage
- Phase I
- Drug Modality
- ADC
Key dates
- Initial CTIS Submission Date
- 04-09-2025
- First CTIS Authorization Date
- 21-11-2025
Trial design
Phase I trial across 2 sites in France.
- Target Sample Size
- 240
Recruitment
- Planned Sample Size
- 240
- Recruitment Window Months
- 55
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 240
France
- Earliest CTIS Part Ii Submission Date
- 05-11-2025
- Latest Decision Or Authorization Date
- 12-03-2026
- Processing Time Days
- 127
- Number Of Sites
- 2
- Number Of Participants
- 120
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Drug Development Department (DITEP)
- Principal Investigator Name
- Anas GAZZAH
- Principal Investigator Email
- anas.gazzah@gustaveroussy.fr
- Contact Person Name
- Anas GAZZAH
- Contact Person Email
- anas.gazzah@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Department of medical oncology
- Principal Investigator Name
- Armelle VINCENEUX
- Principal Investigator Email
- armelle.vinceneux@lyon.unicancer.fr
- Contact Person Name
- Armelle VINCENEUX
- Contact Person Email
- armelle.vinceneux@lyon.unicancer.fr
Sponsor
Primary sponsor
- Full Name
- Janssen Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- JNJ-89862175
- Active Substance
- Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 antibody drug conjugate
- Modality
- ADC
Related trials
Other published trials that may interest you.